| Name | Title | Contact Details |
|---|
LG Chem is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials such as cathodes, as well as drugs and vaccines to deliver differentiated solutions for its customers. LG Chem is committed to reaching carbon-neutral growth by 2030 and net-zero emissions by 2050 by managing the impacts of climate change and making positive contributions to society through renewable energy and responsible supply chains.
ChoiceOne Bank is a community bank holding company based in Michigan, with approximately $2.6 billion in assets. Founded in 1898 as Sparta State Bank, it has grown through strategic mergers and now operates 35 offices across multiple counties. The bank is headquartered in Sparta and has operations centers in Lapeer and Fenton, ensuring efficient service delivery. ChoiceOne offers a wide range of financial services, including digital banking solutions, consumer and commercial banking, agricultural lending, mortgage services, wealth management, payroll solutions, and treasury management. The bank is dedicated to serving a diverse customer base, including families, small businesses, farmers, and low-income individuals, particularly in rural communities. ChoiceOne is committed to being an integral part of Michigan communities, with a mission to provide superior service and quality advice. In 2025, the bank announced a merger with Fentura Financial Inc., enhancing its presence in the Detroit suburbs and expanding into the Flint and Saginaw markets.
Saber Law Group is women- and minority-owned boutique employment law and litigation firm based in San Francisco. * Saber attorneys hit the ground running with deep bench expertise and diverse backgrounds. * Saber attorneys are like legal, business, and operations strategists all in one. * Saber attorneys are driven by clients long-term success, many of whom have stayed with the team for decades. Our brand of client service is in high demand. Were expanding. How do you know youre ready to join Saber? * FOCUSED – You wont let anything stand in between yourself and your end goal. * INSPIRED – You are moved to practice law beyond a paycheck or a title. * RESILIENT – You have crossed hurdles and done anything to get to the finish line. * SOCIAL – You gather to share battle stories and wins at the finish line. * PREPARED – Youre an intricate planner, and preparation is vital for you. You dont just show up and hope for the best. When you turn up, you will be in prime condition. * BRAVE –The legal profession is one of the toughest. At Saber, you will be celebrated.
Your Challenge, Our Passion.📈 Branschens i särklass vassaste stjärnor inom e-handel, digitalisering och digital affärsutveckling under ett och samma tak - Redo att accelerera Er affär. Som experter inom E-handel, digitalisering och affärsutveckling jobbar vi både stort och smått, strategiskt eller operativt – alltid med tillväxt och resultat som vårt främsta fokus. Vi stöttar Er digitala resa och identifierar var ni är idag och vart ni vill vara i framtiden – med lösningarna för att verkställa målen. Din utmaning är vår passion – vi vet vad vi pratar om, på riktigt.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.